Online inquiry

IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15415MR)

This product GTTS-WQ15415MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets HAVCR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_032782.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84868
UniProt ID Q8TDQ0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15415MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4726MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ360MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ5194MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ8078MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ13094MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ5617MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ752MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ4155MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI-754091
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW